Currently, there are three approved PARP inhibitors for ovarian cancer. Most of them were used as monotherapy. Phase 3 VELIA study was aimed to evaluate the efficacy of veliparib plus chemotherapy followed by veliparib maintenance therapy in ovarian cancer. The results showed that the veliparib group has longer median PFS when compared with the control group (23.5 vs. 17.3 months, HR 0.68). In patients with a BRCA mutation, the median PFS was 22.0 and 34.7 months in the control and the veliparib group, respectively (HR 0.44). By contrast, the median PFS of control vs. veliparib group was 15.1 vs. 18.2 months (HR 0.8) in BRCA wild-type patients. Moreover, the effect of veliparib between homologous-recombination deficient (HRD) and homologous-recombination proficient (HRP) patients has also been investigated. In HRD patients, the median PFS was 20.5 and 31.9 months in the control and the veliparib group (HR 0.57). In HRP patients, veliparib treatment had a limited PFS benefit when compared with the control group (median PFS 15.0 vs. 11.5 months, HR 0.81). The above results demonstrated that veliparib is a potent drug for ovarian cancer patients, especially for those with BRCA mutations and HRD.
Source : N Engl J Med. 2019 Sep 28.